Myelofibrosis, a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis, is a very challenging disease to treat, with patients experiencing progressive symptoms that can negatively impact their quality of life. In this excerpt of the transcript from their nursing continuing professional development (NCPD)-approved activity, Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life, Alice Lynn, ANP, an...
Recently, the FDA granted approval to cemiplimab (Libtayo®, Regeneron Pharmaceuticals) for the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) who were previously treated with a hedgehog pathway inhibitor (HHI) or who are ineligible for HHI therapy. In this interview, Karl Lewis, MD, Professor of Medical Oncology at the University of Colorado Anschutz Medical Campus and one of the investigators of Study 1620 (NCT03132636), on which the approval was based, spe...
Today, AstraZeneca voluntarily withdrew the indication of durvalumab (Imfinzi®, AstraZeneca) for patients with previously treated locally advanced or metastatic urothelial carcinoma based on results of the phase 3 DANUBE trial (NCT02516241), which did not meet its primary end points. The withdrawal does not affect durvalumab's indications for non-small cell lung cancer or for extensive stage small-cell lung cancer. Durvalumab, a human monoclonal antibody that binds to programmed death ligand 1 (...
In patients receiving radiotherapy for newly diagnosed metastatic prostate cancer, bone metastasis count and location are associated with overall and failure-free survival, according to an exploratory analysis of the phase 3 STAMPEDE trial. "Prostate radiotherapy improves survival in men with low-burden metastatic prostate cancer," write the investigators in their publication in JAMA Oncology, led by first author Adnan Ali, MBBS, Clinical Research Fellow in the Division of Cancer Sciences at the...
For patients with stage I seminoma, a germ cell tumor of the testicle or other extragonadal locations, post-orchiectomy surveillance with magnetic resonance imaging (MRI) is noninferior to computed tomography (CT) imaging and avoids excess radiation, according to results of the phase 3 Trial of Imaging and Surveillance in Seminoma Testis (TRISST) presented this past weekend at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. "Survival after orchiectomy in stage I...